Thus, aiming at exploring regulatory pathways for a high level of E2F8 in breast cancers, we discovered predictive inhibitors as follows: PIK-93 and NPK76-II-72-1, which could serve as a therapeutic strategy in patients with high expression of E2F8. The gene discussed is E2F8; the disease is breast carcinoma.